Journal
CLINICAL PHARMACOKINETICS
Volume 61, Issue 7, Pages 985-995Publisher
ADIS INT LTD
DOI: 10.1007/s40262-022-01111-8
Keywords
-
Categories
Funding
- Merck
- Pfizer
Ask authors/readers for more resources
The study evaluated the pharmacokinetics of avelumab in pediatric patients with solid tumors. The optimal dose for pediatric patients was determined based on exposure matching with adult data, recommending a lower dose for younger or lighter patients and the adult flat dose for older or heavier patients. This information can inform future avelumab studies, including combination therapies.
Background and Objective A phase I/II trial evaluated the safety, antitumor activity, and pharmacokinetics of avelumab (anti-PD-L1 antibody) in pediatric patients with refractory/relapsed solid tumors (NCT03451825). This study aimed to inform avelumab dose selection in pediatric populations using population pharmacokinetic modeling and simulations. Methods Patients aged Results Pharmacokinetic parameters from 21 patients who received avelumab 10 mg/kg (n = 6) or 20 mg/kg (n = 15) were analyzed. Patients had a wide range of weights and ages (medians, 37.3 kg and 12 years). Exposures with 10-mg/kg dosing were lower vs adult dosing, particularly in patients weighing < 40 kg, whereas 20-mg/kg dosing achieved or exceeded adult exposures, irrespective of body weight. A two-compartment linear model with time-varying clearance using body weight as a covariate, with the frequentist prior approach, best described pediatric data. In this model, optimal overlap in exposure with adult data was achieved with 800 mg every 2 weeks for patients aged >= 12 years and weighing >= 40 kg, and 15 mg/kg every 2 weeks for patients aged Conclusions Based on exposure matching, the recommended doses for further avelumab studies, including combination studies, are 15 mg/kg every 2 weeks for pediatric patients aged < 12 years or weighing < 40 kg and the adult flat dose of 800 mg every 2 weeks for pediatric patients aged >= 12 years and weighing >= 40 kg.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available